a) incubating a cell expressing i) a potassium channel comprising a Kv4.3 or Kv4.2 subunit, or a fragment of a potassium channel comprising a Kv4.3 or Kv4.2 subunit, and ii) a biologically active fragment of a 9q PCIP polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, and 28, wherein said biologically active fragment is selected from the group consisting of an EF domain, residues 68-252 of human 9q, and a Kv4.3 or Kv4.2 potassium channel α subunit binding domain, in the presence and absence of a candidate compound; and

b) determining whether the presence of the candidate compound modulates the interaction of the potassium channel or fragment thereof with said biologically active fragment of said 9q PCIP polypeptide, thereby identifying a compound suitable for treating a cardiovascular disorder.

24. **(Amended)** The method of claim 17 or 19, wherein the EF domain is selected from the group consisting of:

a) residues 116-127, 153-164, 189-200, or 237-248 of SEQ ID NO:14;

b) residues 103-114, 140-151, 176-187, or 224-235 of SEQ ID NO:16;

c) residues 116-127, 153-164, 189-200, or 237-248 of SEQ ID NO:18;

d) residues 98-109, 135-146, 171-182, or 219-230 of SEQ ID NO:20;

e) residues 98-109, 135-146, 171-182, or 219-230 of SEQ ID NO:22;

f) residues 116-127, 103-114, 139-150, or 187-198 of SEQ ID NO:24;

g) residues 66-77, 103-114, 189-200 or 237-248 of SEQ ID NO:26; and

h) residues 98-109, 135-146, 171-182, or 219-230 of SEQ ID NO:28.

Please add new claim 25 as follows:

25. **(New)** A method for identifying a compound suitable for treating a cardiovascular disorder comprising:

a) contacting a polypeptide that is at least 95% identical to a 9q PCIP polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, and 28 and retains a 9q PCIP activity, or a cell expressing said polypeptide with a test compound; and